Diet lays the metabolic groundwork, injections offer pharmacological support, surgery delivers powerful physiological change, ...

In a phase 3 clinical trial, once-daily orforglipron outperformed semaglutide tablets, the best-known oral version of the GLP ...

Your premium access has ended, but the best of Nation.Africa is still within reach. Renew now to unlock exclusive stories and ...

GLP-1s were first approved in 2005 for the treatment of Type 2 diabetes. Since then, more versions of the medication have hit the market, becoming more accessible to patients and used for a wider ...

In a move expected to benefit thousands of New Jersey residents living with obesity and type 2 diabetes, Novo Nordisk, whose U.S. headquarters is based in Plainsboro, announced it will significantly ...

Research challenges the “low-risk” classification in type 2 diabetes, reporting fewer deaths and cardiac events with statins.

Healthy foods like nuts, berries, and fatty fish may be able to help ease obstructive sleep apnea symptoms. However, alcohol, ...

On Thursday, in fact, the Centers for Disease Control and Prevention reported that obesity rates for children and teens ages 2-19 have reached an all-time high — hitting 21.1% between 2021 and 2021, ...

An investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist, orforglipron (Eli Lilly), demonstrated superior ...

Weight loss drugs are more popular than ever, even in cycling, but do the health benefits some are seeing outweigh the risks ...

Eli Lilly and Company has reported detailed findings from the ACHIEVE-3 Phase III trial comparing the efficacy and safety of ...